Fig. 4
 A IFN-ELP(V) and TMZ achieved synergistic treatment after GBM. Cumulative survival of mice after IFN-ELP(V) injection. Local anti-GBM immune response triggered by IFN-ELP(V). (Reproduced with permission from Ref. [49], Copyright 2020, Elsevier Ltd) B Design scheme of IFNa-MMPS-ELP(V) Subcutaneous depot formation after IFNa-MMPS-ELP(V) injection. In vivo therapeutic mechanism of IFNa-MMPS-ELP(V) Melanoma growth inhibition. Survival curve of animals with ovarian cancer. (Reproduced with permission from Ref. [50] Copyright 2019, The Authors) C Composition of ELPdepot-DRA and soluble controls. Different forms of ELP-DRA have similar cytotoxicity to Colo205 as DRA. There was a significant difference in tumor volume between ELPdepot-DRA at day 9 and day 18. (Reproduced with permission from Ref. [55] Copyright 2019, The Authors)